Kyushu University Academic Staff Educational and Research Activities Database
List of Reports
Takeshi Iwasaki Last modified date:2022.12.11

Associate Professor / Division of Diagnostic Pathology / Kyushu University Hospital

1. Okamatsu Y, Tsubouchi K, Iwasaki T, Nakamura T, Nakashima T, Nakatsuru K, Takahata Y, Harada T., Recurrent Massive Hemothorax of Unknown Etiology in an 85-Year-Old Man., Chest, 10.1016/j.chest.2021.09.012., 2022.02.
2. Takeshi Iwasaki, Michiko Matsushita, Daisuke Nonaka, Ichiro Murakami, Kazuhiko Hayashi, Comment on 'Cytokeratin 20-negative Merkel cell carcinoma is infrequently associated with the Merkel cell polyomavirus', Modern Pathology, 10.1038/modpathol.2015.69, Vol.29, No.1, pp.89-90, 2016.01.
3. Kazuya Tsubouchi, Ritsu Ibusuki, Kenji Makisumi, Hirofumi Okamoto, RTakeshi Iwasaki, Yuki Okamatsu, Katsuhiro Inoue, Taishi Harada, Tumor Embolism as a Cause of Renal Artery Occlusion and Acute Kidney Injury Diagnosed and Treated with Endovascular Intervention in a Patient with Mediastinal Undifferentiated Sarcoma, Intern Med., 10.2169/internalmedicine.6249-20, 2021.06.
4. Iwasaki T, Yamamoto H, Oda Y., Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans. , Current treatment options in oncology, 10.1007/s11864-019-0628-3, 2019.03.
5. Iwasaki T, Kodama H, Matsushita M, Kuroda N, Yamasaki Y, Murakami I, Yamamoto O, Hayashi K. , Merkel cell polyomavirus infection in both components of a combined Merkel cell carcinoma and basal cell carcinoma with ductal differentiation; each component had a similar but different novel Merkel cell polyomavirus large T antigen truncating mutation. , Human pathology., 10.1016/j.humpath.2012.08.022., 2013.03.
6. Kiyota M, Oya M, Ayano M, Niiro H, Iwasaki T, Fujiwara M, Oda Y, Fujimoto K, Ida H, First case of pyrin-associated autoinflammation with neutrophilic dermatosis complicated by amyloidosis. , Rheumatology, 10.1093/rheumatology/keaa005., 2020.10.
7. Murakami I, Matsushita M, Iwasaki T, Kuwamoto S, Kato M, Nagata K, Horie Y, Hayashi K, Imamura T, Morimoto A, Imashuku S, Gogusev J, Jaubert F, Takata K, Oka T, Yoshino T. , Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis. , Cell communication and signaling, 10.1186/s12964-015-0092-z, 2015.02.
8. Iwasaki T, Kato M, Horie Y, Kato S, Akatsuka K, Watanabe T, Kuwamoto S, Murakami I, Hayashi K. , A pediatric intramedullary spinal cord tumor with unusual solid-cystic and papillary features: a case report, Neuropathology, 10.1111/j.1440-1789.2011.01209.x., 2011.03.
9. Kanda T, Matsushita M, Iwasaki T, Ishiguro N, Koide T, Hayashi K, Kitamura Y., Multiple Skin Cancers in a Renal Transplant Recipient: A Patient Report with Analyses of Human Papillomavirus and Human Polyomavirus Infection., Yonago acta medica, 2015.10.
10. Kazuya Tsubouchi, Shigesato Inoue, Ritsu Ibusuki, Takeshi Iwasaki, Taishi Harada, Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD-L1., Respirology case reports, 10.1002/rcr2.536, 2020.02, We report herein a case of sarcomatoid malignant pleural mesothelioma (MPM) with high PD-L1 expression who was refractory to standard chemotherapy but had a remarkable and sustained response to nivolumab. A 78-year-old man presented with right chest pain. Computed tomography (CT) showed a solid mass extending to the right pleura. Histopathological examination revealed the proliferation of spindle to pleomorphic ovoid shaped tumour cells, which are positive for calretinin and podoplanin. The patient was diagnosed with sarcomatoid MPM. Despite treatment with carboplatin and pemetrexed, the primary lesion rapidly progressed and new multiple pleural metastases were observed. Although his performance status decreased with advancing of symptoms and adverse events, nivolumab was administered. After the nivolumab treatment, CT showed a significant reduction in pleural tumours with a marked improvement in symptoms. In the primary specimens, TPS of PD-L1 was 80%. The patient has continued this treatment with sustained and remarkable effectiveness with good quality of life (QOL)..